Tango Therapeutics unveiled encouraging phase I/II data for its MTA‑cooperative PRMT5 inhibitor vopimetostat in MTAP‑deleted pancreatic ductal adenocarcinoma, and contemporaneously raised $225 million to advance a pivotal study. The company said response rates and progression‑free survival compared favorably to historical chemotherapy benchmarks in this hard‑to‑treat population, prompting plans for a phase III program next year. The financing is explicitly intended to fund the pivotal trial and expand development. PRMT5 inhibitors are being watched closely by investors and competitors, and Tango’s cash infusion positions it to test whether synthetic‑lethal approaches can translate in PDAC.